Samsung Biologics announced an all-cash tender offer to acquire PolyPeptide Group AG for about CHF 1.46 billion (roughly $1.8 billion), proposing what the company described as its largest-ever acquisition. The deal price is CHF 44.31 per share, and PolyPeptide’s board has unanimously recommended the offer. The acquisition is designed to pivot Samsung Biologics beyond antibodies and antibody-drug conjugates into peptide therapeutics, with particular emphasis on fast-growing demand tied to GLP-1 treatments for obesity and diabetes. Samsung also pointed to PolyPeptide’s integrated peptide development-to-commercial manufacturing footprint across multiple sites. Samsung’s bid is supported by PolyPeptide’s largest shareholder, holding about 55.65% of outstanding shares, which committed to an irrevocable tender undertaking. Samsung said it intends to secure proven peptide manufacturing capabilities and an existing customer base rather than only add capacity. With PolyPeptide having produced more than 1,000 therapeutic peptides historically and carrying a late-stage peptide pipeline, the acquisition aims to create near-term commercial opportunities while building a longer-term platform in a modality the market is increasingly prioritizing.